Related Experiment Video
Updated: May 6, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
Proteomic strategy for probing complementary lethality of kinase inhibitors against pancreatic cancer
Jin-Gyun Lee1, Kimberly Q McKinney, Jean-Luc Mougeot
1Proteomics and Mass Spectrometry Research Laboratory, Carolinas HealthCare System, Charlotte, NC, USA.
Abstract:
In the present study, proteomic analysis was performed to discover combinational molecular targets for therapy and chemoresistance by comparing differential protein expression from Panc-1 cells treated with FDA-approved drugs such as sunitinib, imatinib mesylate, dasatinib, and PD184352. A total of 4041 proteins were identified in the combined data from all of the treatment groups by nano-electrospray ultra-performance LC and MS/MS analysis. Most of the proteins with significant changes are involved in apoptosis, cytoskeletal remodeling, and epithelial-to-mesenchymal transition. These processes are associated with increased chemoresistance and progression of pancreatic cancer. Among the differentially expressed proteins, heme oxygenase-1 (HO-1) was found in the sunitinib and imatinib mesylate treatment groups, which possibly acts as a specific target for synthetic lethality in combinational treatment. HO-1 was found to play a key role in sensitizing the chemoresistant Panc-1 cell line to drug therapy. Viability was significantly decreased in Panc-1 cells cotreated with sunitinib and imatinib mesylate at low doses, compared to those treated with sunitinib or imatinib mesylate alone. The results suggest that induction of chemosensitization by manipulating specific molecular targets can potentiate synergistic chemotherapeutic effects at lower, better tolerated doses, and in turn reduce the toxicity of multidrug treatment of pancreatic cancer.
Insights
This study identified heme oxygenase-1 (HO-1) as a target to overcome chemoresistance in pancreatic cancer. Combining sunitinib and imatinib mesylate sensitized resistant cells, reducing viability and toxicity.
Area of Science:
- Proteomics
- Molecular Biology
- Cancer Therapeutics
Background:
- Pancreatic cancer exhibits significant chemoresistance, hindering effective treatment.
- Identifying novel molecular targets is crucial for overcoming drug resistance and improving therapeutic outcomes.
Purpose of the Study:
- To discover combinational molecular targets for pancreatic cancer therapy and chemoresistance.
- To compare differential protein expression in Panc-1 cells treated with FDA-approved drugs.
Main Methods:
- Proteomic analysis using nano-electrospray ultra-performance LC and MS/MS.
- Comparison of protein expression in Panc-1 cells treated with sunitinib, imatinib mesylate, dasatinib, and PD184352.
- Identification of differentially expressed proteins involved in apoptosis, cytoskeletal remodeling, and epithelial-to-mesenchymal transition.
Main Results:
- 4041 proteins were identified; significant changes were observed in key cancer progression pathways.
- Heme oxygenase-1 (HO-1) was differentially expressed in sunitinib and imatinib mesylate treated groups.
- Co-treatment with low-dose sunitinib and imatinib mesylate significantly decreased Panc-1 cell viability compared to single-drug treatments.
Conclusions:
- Heme oxygenase-1 (HO-1) is a potential target for synthetic lethality in combination therapy for pancreatic cancer.
- Targeting HO-1 can sensitize chemoresistant Panc-1 cells to drug therapy, enhancing chemosensitization.
- Combination therapy potentiates synergistic effects at lower, better-tolerated doses, reducing multidrug toxicity.
More Related Videos
11:23Characterization at the Molecular Level using Robust Biochemical Approaches of a New Kinase Protein
Published on: June 30, 2019
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
